Clinical Trial Update: Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for intralesional MK-4621 (RGT100) in adults with advanced or recurrent tumors (Phase 1/2) has terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MK-4621 (RGT100) (MK-4621 (RGT100))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-07-16